Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
T cells reacting to self-components can promote tissue damage when escaping tolerogenic control mechanisms and may result in autoimmune disease. The current treatments for these disorders are not antigen-specific and can compromise host immunity. We have previously demonstrated that tolerogenic nanoparticles (tNPs) comprised of biodegradable polymers that encapsulate rapamycin co-administered with encapsulated or free antigen (Ag) are capable of inhibiting antigen-specific transgenic T cell proliferation and inducing antigen-specific regulatory T cells (Tregs). Here we further show that tNPs can trigger the expansion of endogenous Tregs specific to a target antigen. The proportion of antigen-specific Treg to total antigen-specific T cells remains constant even after subsequent antigen challenge in combination with a potent TLR7/8 agonist or complete Freunds adjuvant (CFA). Treatment with tNPs provide therapeutic protection in relapsing experimental autoimmune encephalomyelitis (rEAE) that can be transferred to naïve animals. Furthermore, mice treated with tNPs do not develop EAE after adoptive transfer of encephalitogenic T cells. These findings describe a potent therapy to expand Ag-specific Tregs in-vivo and suppress T cell-mediated autoimmunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunopathology of multiple sclerosis
Dendrou, C. A., Fugger, L., & Friese, M. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3871 · Cited by 2,215
Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
Maldonado, R. A., LaMothe, R. A., Ferrari, J. D., Zhang, A.-H., Rossi, R. J., Kolte, P. N., Griset, A. P., O’Neil, C., Altreuter, D. H., Browning, E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408686111 · Cited by 441 · cited 6×
“nanoparticles (nPs) Manufacture of NPs has been previously described (18).”
BackgroundMethodInfluentialSelf-citationTherapeutic Inflammatory Monocyte Modulation Using Immune-Modifying Microparticles
Getts, D. R., Terry, R. L., Getts, M. T., Deffrasnes, C., Müller, M., van Vreden, C., Ashhurst, T. M., Chami, B., McCarthy, D., Wu, H., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007563 · Cited by 378 · cited 1×
“Nanoparticles carrying peptides in the absence of an immunomodulator have been shown to be protective in EAE (47, 48) by targeting MARCO+ macrophages or liver sinusoidal cells.”
BackgroundRay, J. P., Staron, M. M., Shyer, J. A., Ho, P.-C., Marshall, H. D., Gray, S. M., Laidlaw, B. J., Araki, K., Ahmed, R., Kaech, S. M., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.017 · Cited by 315 · cited 1×
“Previous work has shown the necessity of mTOR signaling to promote T cell expansion (29), differentiation (30), and resistance to anergy (31).”
BackgroundA role for mammalian target of rapamycin in regulating T cell activation versus anergy
Zheng, Y., Collins, S. L., Lutz, M. A., Allen, A. N., Kole, T. P., Zarek, P. E., & Powell, J. D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2163 · Cited by 274 · cited 1×
“Previous work has shown the necessity of mTOR signaling to promote T cell expansion (29), differentiation (30), and resistance to anergy (31).”
BackgroundImproving the efficacy and safety of biologic drugs with tolerogenic nanoparticles
Kishimoto, T. K., Ferrari, J. D., LaMothe, R. A., Kolte, P. N., Griset, A. P., O'Neil, C., Chan, V., Browning, E., Chalishazar, A., Kuhlman, W., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.135 · Cited by 201
Self-citationZhang, A.-H., Rossi, R. J., Yoon, J., Wang, H., & Scott, D. W. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2015.11.004 · Cited by 65
Cited by
Feng, X., Xu, W., Li, Z., Song, W., Ding, J., & Chen, X. (2019) · Advanced Science · doi:10.1002/advs.201900101 · Cited by 363
Inducing immune tolerance with dendritic cell-targeting nanomedicines
Cifuentes-Rius, A., Desai, A., Yuen, D., Johnston, A. P. R., & Voelcker, N. H. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00810-2 · Cited by 297
Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 259
Cano, A., Sánchez-López, E., Ettcheto, M., López-Machado, A., Espina, M., Souto, E. B., Galindo, R., Camins, A., García, M. L., & Turowski, P. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0443 · Cited by 144
Sands, E., Kivitz, A., DeHaan, W., Leung, S. S., Johnston, L., & Kishimoto, T. K. (2022) · Nature Communications · doi:10.1038/s41467-021-27945-7 · Cited by 61
Self-citation
Metadata
- Authors
- LaMothe, R. A., Kolte, P. N., Vo, T., Ferrari, J. D., Gelsinger, T. C., Wong, J., Chan, V. T., Ahmed, S., Srinivasan, A., Deitemeyer, P., Maldonado, R. A., & Kishimoto, T. K.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-03-02
- Volume
- 9
- Pages
- 281-281
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2789434908
- Cited by
- 109
- References
- 7
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis. https://app.cochat.ai/papers/10.3389/fimmu.2018.00281
- The paper
- LaMothe, R. A., Kolte, P. N., Vo, T., Ferrari, J. D., Gelsinger, T. C., Wong, J., Chan, V. T., Ahmed, S., Srinivasan, A., Deitemeyer, P., Maldonado, R. A., & Kishimoto, T. K. (2018). Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2018.00281
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.